These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 14992588)

  • 1. G-rich oligonucleotide inhibits the binding of a nuclear protein to the Ki-ras promoter and strongly reduces cell growth in human carcinoma pancreatic cells.
    Cogoi S; Quadrifoglio F; Xodo LE
    Biochemistry; 2004 Mar; 43(9):2512-23. PubMed ID: 14992588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiproliferative activity of a triplex-forming oligonucleotide recognizing a Ki-ras polypurine/polypyrimidine motif correlates with protein binding.
    Cogoi S; Ballico M; Bonora GM; Xodo LE
    Cancer Gene Ther; 2004 Jul; 11(7):465-76. PubMed ID: 15118760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of GC and AT specific DNA minor groove binding drugs on intermolecular triplex formation in the human c-Ki-ras promoter.
    Vigneswaran N; Mayfield CA; Rodu B; James R; Kim HG; Miller DM
    Biochemistry; 1996 Jan; 35(4):1106-14. PubMed ID: 8573565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. (A,G)-oligonucleotides form extraordinary stable triple helices with a critical R.Y sequence of the murine c-Ki-ras promoter and inhibit transcription in transfected NIH 3T3 cells.
    Alunni-Fabbroni M; Pirulli D; Manzini G; Xodo LE
    Biochemistry; 1996 Dec; 35(50):16361-9. PubMed ID: 8973212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression profiling of the influence of RAS mutants on the TGFB1-induced phenotype of the pancreatic cancer cell line PANC-1.
    Fensterer H; Giehl K; Buchholz M; Ellenrieder V; Buck A; Kestler HA; Adler G; Gierschik P; Gress TM
    Genes Chromosomes Cancer; 2004 Mar; 39(3):224-35. PubMed ID: 14732924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of nuclear protein binding to the human Ki-ras promoter by triplex-forming oligonucleotides.
    Mayfield C; Squibb M; Miller D
    Biochemistry; 1994 Mar; 33(11):3358-63. PubMed ID: 8136373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transcriptional targets of hepatocyte growth factor signaling and Ki-ras oncogene activation in colorectal cancer.
    Seiden-Long IM; Brown KR; Shih W; Wigle DA; Radulovich N; Jurisica I; Tsao MS
    Oncogene; 2006 Jan; 25(1):91-102. PubMed ID: 16158056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suppression of Ki-ras p21 levels leading to growth inhibition of pancreatic cancer cell lines with Ki-ras mutation but not those without Ki-ras mutation.
    Aoki K; Yoshida T; Matsumoto N; Ide H; Sugimura T; Terada M
    Mol Carcinog; 1997 Oct; 20(2):251-8. PubMed ID: 9364215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel triplex-forming oligonucleotide targeted to human cyclin D1 (bcl-1, proto-oncogene) promoter inhibits transcription in HeLa cells.
    Kim HG; Miller DM
    Biochemistry; 1998 Feb; 37(8):2666-72. PubMed ID: 9485417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transcription inhibition of oncogenic KRAS by a mutation-selective peptide nucleic acid conjugated to the PKKKRKV nuclear localization signal peptide.
    Cogoi S; Codognotto A; Rapozzi V; Meeuwenoord N; van der Marel G; Xodo LE
    Biochemistry; 2005 Aug; 44(31):10510-9. PubMed ID: 16060660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ki-ras activation in vitro affects G1 and G2M cell-cycle transit times and apoptosis.
    Orecchia R; Infusini E; Sciutto A; Rapallo A; Di Vinci A; Nigro S; Geido E; Giaretti W
    J Pathol; 2000 Mar; 190(4):423-9. PubMed ID: 10699990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncogenic K-Ras down-regulates Rac1 and RhoA activity and enhances migration and invasion of pancreatic carcinoma cells through activation of p38.
    Dreissigacker U; Mueller MS; Unger M; Siegert P; Genze F; Gierschik P; Giehl K
    Cell Signal; 2006 Aug; 18(8):1156-68. PubMed ID: 16257181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Downregulation of c-Ki-ras promoter activity by triplex-forming oligonucleotides endogenously generated in human 293 cells.
    Cogoi S; Suraci C; Del Terra E; Diviacco S; van der Marel G; van Boom J; Quadrifoglio F; Xodo L
    Antisense Nucleic Acid Drug Dev; 2000 Aug; 10(4):283-95. PubMed ID: 10984122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ras-dependent recruitment of c-Myc for transcriptional activation of nucleophosmin/B23 in highly malignant U1 bladder cancer cells.
    Yeh CW; Huang SS; Lee RP; Yung BY
    Mol Pharmacol; 2006 Oct; 70(4):1443-53. PubMed ID: 16857742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of a new G-quadruplex motif in the KRAS promoter and design of pyrene-modified G4-decoys with antiproliferative activity in pancreatic cancer cells.
    Cogoi S; Paramasivam M; Filichev V; Géci I; Pedersen EB; Xodo LE
    J Med Chem; 2009 Jan; 52(2):564-8. PubMed ID: 19099510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The tumor suppressor KLF11 mediates a novel mechanism in transforming growth factor beta-induced growth inhibition that is inactivated in pancreatic cancer.
    Buck A; Buchholz M; Wagner M; Adler G; Gress T; Ellenrieder V
    Mol Cancer Res; 2006 Nov; 4(11):861-72. PubMed ID: 17114344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intra- and intermolecular triplex DNA formation in the murine c-myb proto-oncogene promoter are inhibited by mithramycin.
    Vigneswaran N; Thayaparan J; Knops J; Trent J; Potaman V; Miller DM; Zacharias W
    Biol Chem; 2001 Feb; 382(2):329-42. PubMed ID: 11308031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An anti-K-ras ribozyme suppresses oncogene expression and cell growth of human pancreatic cancer.
    Sakuma T; Kijima H; Nishi M; Abe Y; Yamazaki H; Mine T; Nakamura M; Ueyama Y
    Tokai J Exp Clin Med; 2004 Jun; 29(2):35-42. PubMed ID: 15473338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suppression of polyamine catabolism by activated Ki-ras in human colon cancer cells.
    Ignatenko NA; Babbar N; Mehta D; Casero RA; Gerner EW
    Mol Carcinog; 2004 Feb; 39(2):91-102. PubMed ID: 14750214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor-specific RNAi targeting eIF4E suppresses tumor growth, induces apoptosis and enhances cisplatin cytotoxicity in human breast carcinoma cells.
    Dong K; Wang R; Wang X; Lin F; Shen JJ; Gao P; Zhang HZ
    Breast Cancer Res Treat; 2009 Feb; 113(3):443-56. PubMed ID: 18327707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.